SI-BONE, Inc. will announce Q4 2024 financial results on February 24, 2025, followed by a conference call.
Quiver AI Summary
SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, after market close. A conference call with management will take place at 1:30 p.m. PT, during which investors can participate by registering online or by accessing a webcast on the company's website. SI-BONE is recognized as a leader in minimally invasive surgical treatments for sacropelvic issues and has a strong track record with over 115,000 procedures performed. The company has a robust body of clinical evidence backing its technologies and has expanded into related markets. For further details, investors can contact Saqib Iqbal.
Potential Positives
- Announcement of financial results reporting for Q4 and full year 2024, indicating transparency and engagement with investors.
- Hosting a conference call for investors, enhancing direct communication and investment relations.
- Recognition as a global leader in surgical treatment technologies for sacropelvic disorders, showcasing industry leadership and innovation.
- Established clinical evidence supporting SI-BONE’s technologies, reinforcing trust and credibility in the company's product offerings.
Potential Negatives
- The announcement of the upcoming financial results may indicate previous uncertainty or concerns regarding the company's financial performance, potentially affecting investor confidence.
- There is no mention of expected revenue or performance metrics for the quarter, which could be perceived as a lack of transparency or positive outlook by the company.
- The need for registration to listen to the conference call may limit the number of investors and stakeholders able to access the information directly, possibly impacting communication effectiveness.
FAQ
When will SI-BONE report its financial results for 2024?
SI-BONE will report its financial results after market close on February 24, 2025.
How can I listen to SI-BONE's conference call?
You can listen to the conference call by registering at https://edge.media-server.com/mmc/p/xyxunb4k.
Where can I find the archived webcast of the conference call?
The archived webcast will be available for replay on the "Investors" section of SI-BONE's website for at least 90 days.
What technologies does SI-BONE specialize in?
SI-BONE specializes in technologies for the surgical treatment of sacropelvic disorders and minimally invasive SI joint surgery.
What innovative solutions has SI-BONE developed?
SI-BONE has developed solutions for adult deformity, sacropelvic fixation, and pelvic trauma, leveraging its expertise in SI joint fusion.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SIBN Insider Trading Activity
$SIBN insiders have traded $SIBN stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.
Here’s a breakdown of recent trading of $SIBN stock by insiders over the last 6 months:
- ANTHONY J RECUPERO (President, Commercial Ops) has made 0 purchases and 13 sales selling 19,895 shares for an estimated $266,826.
- LAURA FRANCIS (Chief Executive Officer) has made 0 purchases and 10 sales selling 20,015 shares for an estimated $264,323.
- ANSHUL MAHESHWARI (Chief Financial Officer) has made 0 purchases and 10 sales selling 14,880 shares for an estimated $206,281.
- JEFFREY W DUNN has made 0 purchases and 3 sales selling 3,530 shares for an estimated $46,489.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SIBN Hedge Fund Activity
We have seen 68 institutional investors add shares of $SIBN stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 978,788 shares (-37.9%) from their portfolio in Q3 2024, for an estimated $13,683,456
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 947,074 shares (-38.3%) from their portfolio in Q3 2024, for an estimated $13,240,094
- CHAMPLAIN INVESTMENT PARTNERS, LLC added 358,821 shares (+14.7%) to their portfolio in Q3 2024, for an estimated $5,016,317
- MILLENNIUM MANAGEMENT LLC removed 239,949 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,354,487
- IMPAX ASSET MANAGEMENT GROUP PLC added 221,604 shares (+41.3%) to their portfolio in Q3 2024, for an estimated $3,098,023
- HARBOR CAPITAL ADVISORS, INC. added 220,555 shares (+35.5%) to their portfolio in Q4 2024, for an estimated $3,092,181
- NUVEEN ASSET MANAGEMENT, LLC added 201,828 shares (+23.2%) to their portfolio in Q3 2024, for an estimated $2,821,555
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k . Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com . The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com .
iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal, [email protected]